Associations of CTCF and FOXA1 with androgen and IGF pathways in men with localized prostate cancer

被引:1
作者
Barker, Rachel [1 ]
Biernacka, Kalina [1 ]
Kingshott, Georgina [1 ]
Sewell, Alex [2 ]
Gwiti, Paida [2 ,3 ]
Martin, Richard M. [4 ,5 ,6 ]
Lane, J. Athene [7 ]
McGeagh, Lucy [8 ]
Koupparis, Anthony [9 ]
Rowe, Edward [9 ]
Oxley, Jon [2 ]
Perks, Claire M. [1 ]
Holly, Jeff M. P. [1 ]
机构
[1] Southmead Hosp, Bristol Med Sch, IGF & Metab Endocrinol Grp, Translat Hlth Sci, Learning & Res Bldg, Bristol BS10 5NB, England
[2] Southmead Hosp, Dept Cellular Pathol, North Bristol NHS Trust, Bristol BS10 5NB, England
[3] North West Anglia NHS Fdn Trust, Dept Pathol, Peterborough PE3 2PS, England
[4] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, 39 Whatley Rd,Canynge Hall, Bristol BS8 2PS, England
[5] Univ Hosp Bristol, Biomed Res Ctr, Natl Inst Hlth Res, Lower Maudlin St, Bristol BS1 2LY, England
[6] Weston NHS Fdn Trust & Univ Bristol, Univ Hosp Bristol Educ Ctr, Dent Hosp, Biomed Res Unit Off, Lower Maudlin St, Bristol BS1 2LY, England
[7] Univ Bristol, Bristol Trials Ctr, Bristol Med Sch, Populat Hlth Sci, 39 Whatley Rd,Canynge Hall, Bristol BS8 2PS, England
[8] Oxford Brookes Univ, Oxford Inst Nursing, Fac Hlth & Life Sci, Support Canc Care Res Grp,Midwifery & Allied Hlth, Jack Straws Lane, Oxford OX3 0FL, England
[9] Southmead Hosp, Bristol Urol Inst, Dept Urol, Bristol BS10 5NB, England
基金
英国医学研究理事会;
关键词
IGF; CTCF; FOXA1; Prostate cancer; Androgen signaling; FORKHEAD BOX A1; RECEPTOR-BINDING; RISK VARIANTS; EXPRESSION; REVEALS; BREAST; MASTER; H19;
D O I
10.1016/j.ghir.2023.101533
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To examine associations between the transcription factors CCCTC-binding factor (CTCF) and forkhead box protein A1 (FOXA1) and the androgen receptor (AR) and their association with components of the insulin-like growth factor (IGF)-pathway in a cohort of men with localized prostate cancer.Methods: Using prostate tissue samples collected during the Prostate cancer: Evidence of Exercise and Nutrition Trial (PrEvENT) trial (N = 70 to 92, depending on section availability), we assessed the abundance of CTCF, FOXA1, AR, IGFIR, p-mTOR, PTEN and IGFBP-2 proteins using a modified version of the Allred scoring system. Validation studies were performed using large, publicly available datasets (TCGA) (N = 489).Results: We identified a strong correlation between CTCF and AR staining with benign prostate tissue. CTCF also strongly associated with the IGF-IR, with PTEN and with phospho-mTOR. FOXA1 was also correlated with staining for the IGF-IR, with IGFBP-2 and with staining for activated phosphor-mTOR. The staining for the IGF-IR was strongly correlated with the AR.Conclusion: Our findings emphasise the close and complex links between the endocrine controls, well known to play an important role in prostate cancer, and the transcription factors implicated by the recent genetic evidence.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression
    Su, Yiming
    Zhang, Yu
    Zhao, Jing
    Zhou, Wenhao
    Wang, Wenhao
    Han, Bangmin
    Wang, Xiaohai
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (11) : 3225 - 3243
  • [32] Androgen and prostate cancer: the role of primary androgen deprivation therapy in localized prostate cancer
    Namiki, Mikio
    Kitagawa, Yasuhide
    Mizokami, Atsushi
    Koh, Eitetsu
    JOURNAL OF MENS HEALTH, 2008, 5 (04) : 333 - 341
  • [33] FOXA1 is a determinant of drug resistance in breast cancer cells
    Kumar, Uttom
    Ardasheva, Anastasia
    Mahmud, Zimam
    Coombes, R. Charles
    Yague, Ernesto
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 317 - 326
  • [34] Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype
    Robinson, J. L. L.
    Hickey, T. E.
    Warren, A. Y.
    Vowler, S. L.
    Carroll, T.
    Lamb, A. D.
    Papoutsoglou, N.
    Neal, D. E.
    Tilley, W. D.
    Carroll, J. S.
    ONCOGENE, 2014, 33 (50) : 5666 - 5674
  • [35] SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer
    Hernandez-Llodra, Silvia
    Segales, Laura
    Safont, Ainara
    Juanpere, Nuria
    Lorenzo, Marta
    Fumado, Lluis
    Rodriguez-Vida, Alejo
    Cecchini, Lluis
    Bellmunt, Joaquim
    Lloreta-Trull, Josep
    PROSTATE, 2019, 79 (10) : 1156 - 1165
  • [36] Predicting FOXA1 gene mutation status in prostate cancer through multi-modal deep learning
    Lin, Simin
    Deng, Longxin
    Hu, Ziwei
    Lin, Chengda
    Mao, Yongxin
    Liu, Yuntao
    Li, Wei
    Yang, Yue
    Zhou, Rui
    Lai, Yancheng
    He, Huang
    Tan, Tao
    Zhang, Xinlin
    Tong, Tong
    Ta, Na
    Chen, Rui
    BIOMEDICAL SIGNAL PROCESSING AND CONTROL, 2025, 106
  • [37] Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial
    Guiu, Severine
    Charon-Barra, Celine
    Vernerey, Dewi
    Fumoleau, Pierre
    Campone, Mario
    Spielmann, Marc
    Roche, Henri
    Mesleard, Christel
    Arnould, Laurent
    Lemonnier, Jerome
    Lacroix-Triki, Magali
    FUTURE ONCOLOGY, 2015, 11 (16) : 2283 - 2297
  • [38] Prognostic value of FOXA1 in breast cancer: A systematic review and meta-analysis
    Shou, Jiafeng
    Lai, Yucheng
    Xu, Jinming
    Huang, Jian
    BREAST, 2016, 27 : 35 - 43
  • [39] AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer
    Zhou, Meng
    Gan, Xing-li
    Ren, Yue-xiang
    Chen, Qian-xin
    Yang, Yuan-zhong
    Weng, Zi-jin
    Zhang, Xiao-fang
    Guan, Jie-xia
    Tang, Lu-ying
    Ren, Ze-fang
    BMC CANCER, 2023, 23 (01)
  • [40] Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer
    BenAyed-Guerfali, Dorra
    Dabbeche-Bouricha, Emna
    Ayadi, Wajdi
    Trifa, Fatma
    Charfi, Slim
    Khabir, Abdelmajid
    Sellami-Boudawara, Tahia
    Mokdad-Gargouri, Raja
    MOLECULAR BIOLOGY REPORTS, 2019, 46 (03) : 3247 - 3255